Nice to see some posts on CYT. Just have to make sure Pheenom of...

Nice to see some posts on CYT. Just have to make sure Pheenom of SRX infamy does not get wind.

CYT are making excellent clinical trial progress with their lead oncology candidates and are actually in a similar position to Progen, which was bought heavily inthe lead up to the presentation of positive trial results at AHPBA meeting in US the past month.

My understanding is net assest backing for CYT is around 60 cents, so there is very little premium priced in for advanced stage of development of the CYT 997 and other candidate. I know JT Campbell rate CYT as a buy up to 80 cents.